FDA 483 OBSERVATION · #136 OF 1,923 MOST-CITED
Process preventive controls - Appropriate (Adequate)
FDA cited this observation 221 times across 209 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
What this grouping is not
An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.
What this observation means, and how to comply
SPEQ's practitioner reading of this finding. The regulatory basis is a cited fact; the interpretation, compliance steps, and root causes are SPEQ synthesis — not an FDA classification of the citation.
A process preventive control was present but not appropriate or adequate to significantly minimize or prevent the hazard — the critical limit was set too loose, the parameter chosen did not actually control the hazard, or the control was not validated for the product and process. This is the adequacy question for process controls under §117.135(c)(1).
Why FDA writes it — An inadequate process control gives the appearance of a kill or reduction step while the hazard survives — a cook that is time/temperature-insufficient or a pH target that does not reach the target organism. FDA cites adequacy because a process control must be scientifically capable of controlling the hazard, not just be a step in the flow.
- Establish critical limits from a valid scientific basis (process authority study, published thermal-death data, challenge study) for the specific product.
- Confirm the chosen parameter genuinely controls the identified hazard and covers the worst-case product configuration and load.
- Validate the process control before relying on it and revalidate after formulation or equipment changes.
- Document the adequacy rationale in the food safety plan so the critical limit is defensible, not arbitrary.
- Critical limits copied from a similar product or set by convention rather than derived from a validated study for this formulation.
- No revalidation after a recipe, packaging, or equipment change quietly moved the process outside the original validated envelope.
How to close this finding — and stop it recurring
What this observation is associated with
Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 1.4× the rate of the average FDA-cited firm (11.0% vs 7.8%), across 209 FEI-matched firms.
This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.
How FDA worded it — real examples
Your written process preventive control, monitoring, corrective action and verification procedures were not appropriate to significantly minimize or prevent the hazard requiring a preventive control.
Your written process preventive control and monitoring procedures were not appropriate to significantly minimize or prevent the hazard requiring a preventive control.
Your written process verification procedures were not appropriate to significantly minimize or prevent the hazard requiring a preventive control.
Your written process verification procedures were not appropriate to significantly minimize or prevent the hazard requiring a preventive control.
Your written process preventive control procedures were not appropriate to significantly minimize or prevent the hazard requiring a preventive control.
Your written process preventive control, monitoring, corrective action and verification procedures were not appropriate to significantly minimize or prevent the hazard requiring a preventive control.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →